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Abstract Focal chondral or osteochondral lesions can be
painful and disabling because they have insufficient intrinsic
repair potential, and constitute one of the major extrinsic risk
factors for osteoarthritis (OA). Attention has, therefore, been
paid to regenerative therapeutic procedures for the early treat-
ment of cartilaginous defects. Current treatments for OA are
not regenerative and have little effect on the progressive
degeneration of joint tissue. One major reason for this under-
representation of regenerative therapy is that approaches to
treating OA with cell-based strategies have to take into con-
sideration the larger sizes of the defects, as compared with
isolated focal articular-cartilage defects, and the underlying
disease process. Here, we review current treatment strategies
using mesenchymal stem cells (MSCs) for chondral and
osteochondral tissue repair in trauma and OA-affected joints.
We discuss tissue-engineering approaches, in preclinical
large-animal models and clinical studies in humans, which
use crude bone-marrow aspirates and MSCs from different
tissue sources in combination with bioactive agents and
materials.
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Introduction
Focal chondral or osteochondral lesions can be painful and
disabling, and predispose patients to osteoarthritis (OA). For
long-term repair and regeneration of these defects, cells alone
or in combinationwith biomaterials are implanted at the site of
injury. However, not much attention has been paid to micro-
environmental effects of the neighboring cartilage and
subchondral bone. This is particularly evident in diseases
affecting diarthrodial joints, including OA, which is an age-
related and/or trauma-induced multi-factorial, slowly
progressing, and primarily non-inflammatory degenerative
disorder of the synovial joints culminating in the irreversible
destruction of the articular cartilage. As well as metabolic
imbalance, activation of the whole endochondral-ossification
program, starting with cell proliferation through articular-
chondrocyte hypertrophy and apoptosis, has been identified
as an important determinant of OA progression [1–4].
Articular cartilage lesions greater than 5 mm2 do not heal
spontaneously [5], and for therapy it must be kept in mind that
cartilage defects are multifactorial and site-specific and thus
need both a clear analysis of the underlying pathology and
individualized therapy. Chondral or osteochondral lesions of
any type are found in 61 % of patients with joint pain and are
the most prevalent indication for surgical cartilage repair. The
incidence of severe International Cartilage Repair Society
(ICRS) grade III lesions and of full chondral ICRS grade IV
defects in knee joints are approximately 40 % and 19 %,
respectively [6]. If left untreated they lead, after a long asymp-
tomatic interval, to full clinical OA. It has been suggested that
cartilage repair surgery may be most suitable for patients
younger than 40–50 years. Attention, therefore, has been paid
to therapeutic procedures for the early treatment of cartilagi-
nous defects. The advantage of local defects is that they are
contained within healthy cartilage and bone, and it is likely
that delivery of specific growth factors and other
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chondroprotective factors to defect sites will support cartilage
healing. Early treatment of cartilaginous lesions could indeed
be crucial to slowing down the chronic development of OA.
The major challenges in regenerative medicine for cartilage
are restoration of a biomechanically competent extracellular
matrix (ECM) and intimate integration of this newly synthe-
sized matrix within the resident tissue. To address this specific
challenge, autologous chondrocyte implantation (ACI) was
developed and has prepared the way for novel cell-based
therapy and biomaterial-assisted cartilage engineering [7].
Current treatments for OA are not regenerative and have
little effect on the progressive degeneration of joint tissue.
Clinical interventions are primarily symptomatic, with a focus
on pain reduction and control of inflammation using non-
steroidal anti-inflammatory drugs and, ultimately, total joint
replacement [8, 9]. One major reason for this underrepresen-
tation of regenerative therapy is that approaches for treating
OAwith cell-based strategies have to take into consideration
both the larger sizes of the defects and the underlying disease
process. Fragile neocartilage constructs produced by im-
planted or injected mesenchymal stem cells (MSCs) or
chondrocytes may undergo rapid degradation when situated
in inflamed or diseased joints. Therefore the underlying pa-
thology must be brought effectively under control, because
otherwise any cell-based treatment strategy of OA is unlikely
to be successful long-term. This knowledge implies that car-
tilage repair lacks a one-for-all therapy.
Here, we present up-to-date treatment strategies using
MSCs for chondral and osteochondral tissue repair in post-
traumatic and OA-affected joints. We have reviewed current
literature for tissue-engineering approaches in preclinical
large-animal models and clinical studies of humans using
crude bone-marrow concentrate (BMC) and MSCs from dif-
ferent tissue sources in combination with other agents.
Figure 1 gives an overview of preclinical and clinical studies
referred to in this review.
Clinical-Application Techniques for Autologous BMC and/or
MSC
In principal, two strategies exist for the clinical application of
cultured and expanded cells (autologous chondrocytes or
MSCs) or cell suspensions (autologous bone-marrow concen-
trates or whole blood): surgical treatment and injection. Sur-
gical delivery of cells includes transplantation or implantation
of cells into the chondral and osteochondral defects. The
advantage of this approach is the direct and targeted applica-
tion on the lesion site; the disadvantage is the invasiveness of
the approach, which requires opening of the joint cavity.
Intraarticular injections are less invasive, which makes appli-
cation easier; however, there is no precise way of delivering
the cells to the defect site. Depending on the application
method, the suspension can be injected directly into the
diseased tissue, where the cells eventually populate the target
site and stimulate repair via autocrine or paracrine pathways.
With respect to human therapy, injection of whole blood or
bone marrow, or concentrates thereof, can usually be per-
formed in the operating theatre without major regulatory
obstacles. The administration of cell preparations expanded
ex vivo requires strict compliance with good medical practice
(GMP) and nation-specific requirements.
Bone-marrow concentrate has attracted much interest from
orthopedic surgeons as a third-generation intra-articular
orthobiological injectable therapy for cartilage disease.
Bone-marrow concentrate contains MSC, hematopoietic stem
cells, platelets (containing growth factors), and cytokines. The
anti-inflammatory and immunomodulatory properties of
bone-marrow-derived mesenchymal stem cells (BMSC) or
adipose-derived stem cells (ADSC) can facilitate regeneration
of tissue. Although marrow suspensions are believed to con-
tain a higher percentage of stromal cells than peripheral blood,
both are crude mixtures with low overall abundance of MSCs
and undefined mixtures of proteins. The MSC density can be
increased by centrifugation of whole blood or marrow, recov-
ery from cell filters, clotting, or other concentration methods.
These methods are relatively simple, making them appealing
for single-step usage procedures in the operating theatre, and,
therefore, are not associated with major regulatory obstacles.
Alternatively cells, and in particular MSCs, can be harvest-
ed from blood, bone marrow, or, after digestion, other tissues
via their adherence to plastic surfaces. Such cell populations
are usually maintained in tissue culture for amplification under
controlled GMP conditions using autologous serum. This
method offers the opportunity for close monitoring of the cells
regarding safety and quality aspects, and for further cell se-
lection. However, this clinical approach has the greatest reg-
ulatory obstacles in the specific requirements of each country
and continent (European Medicines Agency and U.S. Food
and Drug Administration). The use of unprocessed and ex-
vivo-processed cells might be enhanced and supplemented by
the use of biomaterial scaffolds, soluble growth factors,
nucleic acids, or mechanical stimulation. Additional specific
regulatory requirements must be met for the use of each of
these supplements and for their combined usage, indicating
the complexity of such approaches from a biological, medical,
and regulatory perspective (reviewed in Refs. [10, 11•]).
Treatment of Chondral and/or Osteochondral Lesions
with MSC in Preclinical Studies Using Large-Animal Models
The average human articular-cartilage thickness is 2.2–
2.5 mm [12] and the average defect size is approximately
550 mm3 [6, 13], with 95 % of defects involving cartilage
only and not affecting subchondral bone [6, 14]. For testing
cell-based treatments, a perfect animal model should mimic as
precisely as possible the human defect and articular-cartilage
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morphology. A variety of animal models for cartilage lesions
are described in literature, ranging from murine, laprine, ca-
nine, ovine, porcine, and caprine to equine models (reviewed
in Ref. [14]). Small-animal models, for example mouse and
rabbit, are often used as proof-of-concept, but articular carti-
lage is thinner and defects are much smaller compared with
humans; in addition, most defects cannot be set without pen-
etrating the subchondral bone plate. Therefore, especially for
preclinical studies, large animals including swine, sheep, or
horse are more appropriate for modelling human articular-
cartilage defects and testing the regenerative capacity of cell-
based treatments. The following section presents a compre-
hensive overview of published studies on MSC-based treat-
ment for regenerating localized chondral and osteochondral
defects in ovine, porcine, and equine animal models. Table 1
summarizes conditions and treatment outcomes.
Ovine Models
Sheep are commonly used as animal models for chondral and
osteochondral defects, because these animals are readily avail-
able, easy to handle, and relatively inexpensive. In addition,
the anatomy of the knee joint is similar to that of humans and
“second look” arthroscopy is possible. Furthermore, the ovine
medial femoral condyle cartilage thickness of 0.4–1.7 mm
[12, 27]—although thinner than that of humans—enables
production of partial and full-thickness defects that do not
penetrate the subchondral bone plate [14]. In osteochondral
defects the bone marrow is opened, and one likely situation is
that endogenous BMSCs migrate from the bone marrow into
the defect, thus contributing to the repair tissue in a manner
comparable to the BMSC implant. This setting makes it
impossible to determine whether implanted cells or endoge-
nous cells are responsible for defect healing. To circumvent
this situation, one ovine study conducted by Mrugala et al.
[15] implanted autologous ovine BMSCs into a partial-thick-
ness-cartilage-defect model. BMSCs in passage 1 were mixed
with blood and/or chitosan scaffold and/or TGF-β3, and the
clots generated were filled into cartilage defects set in the
internal groove of the patella. The authors observed that
BMSCs or the scaffold alone had poor ability to repair these
defects, whereas BMSC in the presence of TGF-β3 and
chitosan-based-scaffold-generated tissue was positive for
aggrecan and collagen II, indicating hyaline-like repair tissue.
After two months the defects were filled with this cartilage-
like tissue; this tissue was only moderately integrated with the
surrounding cartilage, indicating that investigations at later
time points are required to observe full integration of newly
formed tissue occurring after several months (Table 1).
For BMSC treatment of ovine osteochondral defects, five
studies have been reported. A novel, promising approach
seems to be the application of BMSCs that have been pre-
differentiated ex vivo to the chondrogenic stage; this strategy
was tested in three studies by the same group using
Fig. 1 Overview of preclinical and clinical studies of treatment of
traumatic and osteoarthritis-induced defects with mesenchymal stem cells
(MSCs) discussed in this review. ADSC = adipose-tissue-derived stem
cells, BMC = bone-marrow concentrate, BMSC = bone-marrow-derived
mesenchymal stem cells
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comparable experimental setups [16, 17•, 18]. A unique as-
pect of these three studies was that the treatment was per-
formed six weeks after defect setting, whereas in all other
large-animal studies defects were treated directly after setting.
Delaying treatment after defect setting creates a clinically
relevant situation that resembles chronic post-traumatic hu-
man OA. In the first study by Zscharnack et al. [16], pre-
differentiated BMSCs achieved better regenerative results
after six months, as measured by gross appearance and
O’Driscoll [28] and ICRS [29] scores with respect to collagen
II content and hyaline-cartilage appearance, than undifferen-
tiated BMSCs, collagen I gels alone, and untreated controls.
However, integration of newly formed cartilage-like tissue
was incomplete at six months, and the important question of
whether the BMSCs had adopted a stable chondrogenic phe-
notype, without further progression to hypertrophy at time
points beyond six months, was not addressed. In the second
study, Marquass et al. [17•] compared the regenerative capac-
ity of ex-vivo-pre-differentiated BMSCs with differentiated
autologous articular chondrocytes after 12 months, and found
higher O’Driscoll [28] and ICRS scores with pre-
differentiated BMSCs in collagen I gels than with
chondrocytes in MACT gels, undifferentiated BMSCs in gels,
and untreated controls. Furthermore, repair tissue generated
by pre-differentiated BMSCs had no sign of degradation
within one year. In this line, the approach was enhanced by
embedding pre-differentiated BMSCs into triphasic constructs
[18]. These triphasic constructs were compared with standard
osteochondral autografting (OATS), again using an ovine
osteochondral-defect model. At six months no significant
difference in histological scores between the two groups was
detected. At this time point the triphasic-construct group had
superior cartilage bonding, whereas at 12 months the OATS
group had superior cartilage-matrix morphology. Because of
an observed sinking of the triphasic constructs, and a high
variability in the quality of the repaired tissue, the authors did
not believe the triphasic construct superior to OATS. A study
from Guo et al. [19] used BMSCs without pre-differentiation
seeded on β-tricalcium phosphate (TCP) implants for treat-
ment of osteochondral defects. After six months, hyaline-like
tissue covered the surfaces of the defects and a perfect inter-
face between engineered tissue, the adjacent cartilage, and
underlying bone was observed, whereas in control groups
(β-TCP scaffold and untreated) the defects were clearly visi-
ble and incompletely repaired. The authors concluded that
undifferentiated MSCs on β-TCP scaffolds have promising
potential for clinical application. The last ovine study ana-
lyzed the regenerative capacity of undifferentiated BMSCs
seeded in titanium implants into large osteochondral defects.
After six months, Frosch et al. [20] found that 50% of BMSC-
coated implants were osseo-integrated, with complete regen-
eration of subchondral bone; the regenerated cartilage
contained collagen I and collagen II, indicating hyaline-like-
cartilage regeneration. In contrast, the other 50 % of the
BMSC-coated implants, the cell-free implants, and the non-
treated controls had incomplete healing, osseo-integration
failure, and formation of fibrocartilage instead of hyaline
cartilage (Table 1).
Porcine Models
Pigs are not commonly used for cartilage-defect research,
because of handling difficulties and logistical requirements
regarding housing. A point in favor of using pigs is that the
articular cartilage thickness of 1.5–2.0 mm [12, 30, 31] is
more similar to humans than that of ovine cartilage and
enables easier production of partial and full-thickness defects
without penetrating the subchondral bone plate [14], better
reflecting human articular-cartilage defects.
Proof of a stable in-vivo cartilaginous-tissue phenotype of
implanted BMSCs is the focus of a study by Steck et al. [21].
The group analyzed expression of collagens II and X and of
MMP-13 to compare the performance of BMSCs pre-
differentiated in vitro to a chondrogenic stage versus undif-
ferentiated BMSCs when implanted into minipigs with acute,
full-thickness cartilage defects on the trochlear ridge of the
femur. Defects were filled with the undifferentiated BMSCs
and sealed with a collagen I and III matrix and commercial
fibrin glue. Follow-up times for assessment of morphological
and molecular tissue aspects were up to eight weeks. The data
revealed that, in comparison to the pre-differentiated BMSCs,
the application of undifferentiated BMSC in the orthotopic
environment resulted in lower COL10A1/COL2A1 and
MMP13/COL2A1 mRNA ratios. The reason for the discrep-
ancy between in-vitro and in-vivo results is poorly under-
stood, and the authors speculated that unknown signaling
molecules and biomechanical stimuli derived from neighbor-
ing cartilage and/or bone tissue may have an important effect.
On the basis of their data, they regarded application of BMSCs
pre-differentiated ex vivo as unfavorable for cartilage repair
until better in-vitro induction procedures for chondrogenesis
become available. In addition, to obtain a repair tissue com-
parable to healthy cartilage, a study duration of eight weeks is
too short.
The regenerative capacity of BMSCs in porcine
osteochondral defects was reported in three studies. Zhou
et al. [22] analyzed the repair capacity of pre-differentiated
and undifferentiated BMSCs in biodegradable PGA–PLA
scaffolds. After six months, both groups with cells had better
reparative results regarding gross appearance and histology
than were obtained for the group with scaffold alone and the
untreated group. Repair tissue of pre-differentiated BMSCs
had almost normal cartilage and subchondral-bone-like prop-
erties. Concerning the question of if and for how long im-
planted BMSCs remain in the defect, a study revealed that
GFP-labeled implanted BMSCs are located in the regenerated
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cartilage-like tissue and subchondral bone even after seven
months of follow-up. In a carefully designed and evaluated
study, Ho et al. [23] used undifferentiated BMSCs embedded
with fibrin in polycaprolactone (PCL) and PCL–TCP scaf-
folds and covered the defect with PCL–collagen electrospun
mesh. In contrast with the findings of Zhou et al., defects were
set in weight-bearing areas (medial condyle and patellar
groove) of the joint. After six months, BMSCs and PCL–
collagen electrospun mesh had a positive effect on morpho-
logical outcomes of cartilage-like repair tissue. Notably,
healing was inferior at the patellar groove compared with the
medial condyle, and this was attributed to site-specific biome-
chanical features.
Chang et al. [24•] obtained better histological Pineda scores
[32] with undifferentiated BMSCs compared with differenti-
ated BMSCs, collagen I matrix alone, or untreated defects in
minipigs after six months. However, the quality of the regen-
erated tissue was inferior and did not differ significantly
between experimental and control groups. In contrast with
the two previously described studies, osteochondral defects
were smaller—which may explain the high degree of sponta-
neous healing of non-treated defects—when BMSCs were
used at higher passages without scaffolds inserted into the
defect (Table 1).
Equine Models
The horse is the largest model available and, having an aver-
agemedial-femoral-condyle-cartilage thickness of 1.75–2mm
[33], it has even more similarity to human cartilage in thick-
ness than other large-animal models. “Second look” arthros-
copy is possible, and partial or full-thickness cartilage defects
without penetration of the subchondral bone plate can be set.
However, the horse is a companion animal and thus ethical
aspects are an important factor. Furthermore, horses are not
bred specifically for biomedical research, handling is difficult,
and housing is very expensive [14].
In Wilke et al. [25], 15 mm full-thickness cartilage defects
were set in the femoral patella and filled with undifferentiated
BMSCs embedded in autologous fibrin. A second-look ar-
throscopy and biopsy were obtained for each animal after
30 days and animals were euthanized after eight months.
Short-term assessment revealed a significant improvement of
arthroscopy scores and increased collagen II-containing fi-
brous tissue in defects treated with BMSCs compared with
those treated with fibrin matrix alone. However, long-term
assessment revealed no difference in BMSC-treated defects
compared with those treated with fibrin matrix alone regard-
ing GAG and/or collagen II content and matrix biochemical
assays. For both groups, the repair tissue differed markedly
from normal cartilage in cartilage-quality scores and biochem-
ical properties. In this study defect healing might be affected
by compromised motion because, after recovery from
anesthesia, the horses were housed without exercise for five
weeks and then with a daily exercise regimen of a 5 min walk
for a further seven weeks.
Seo et al. [26•] analyzed the repair capacity of BMSCs
loaded on biphasic sponge scaffolds and implanted in
osteochondral defects. The chondrogenic layer consists of a
acidic gelatin–β-tricalcium phosphate (GT) sponge loaded
with platelet-rich plasma, BMSCs, and chondrogenically dif-
ferentiated BMSCs (without TGF-β), whereas the osteogenic
layer is composed of a basic GT sponge loaded with BMP-2
and BMSCs. After four months, the test group had signifi-
cantly higher radiographic, QCT, macroscopic, and histolog-
ical scores than the control group with biphasic sponge and
without cells or growth factors (Table 1).
Comparison to Human Situation
Despite the fact that 95 % of human defects are of chondral
and not osteochondral nature [6, 14], only a few pre-clinical
studies [15, 21, 25] have created isolated chondral defects to
analyze the cartilage-regeneration capacity of BMSCs. Fur-
thermore, most studies suffer from too-short follow-up
times—usually less than 12 months—which do not enable
satisfactory analysis of repair tissue with respect to stability of
the chondrogenic phenotype, hyaline-like appearance, defect-
site integration, and biomechanical characteristics. For
osteochondral defects, all large-animal studies, irrespective
of the animal model, reported improvement in regeneration
when BMSCs were used for defect repair [16, 17•, 20, 22, 23,
24•, 25]. A beneficial effect of an additional ex-vivo pre-
differentiation phase of MSCs is a matter of debate on the
basis of current knowledge [16, 17•, 21, 22].
Several aspects remain to be addressed in future studies,
including the effect of animal age on the extent of repair of
chondral defects at weight-bearing areas. Importantly, only the
three ovine studies from the Leipzig group featured a study
design with a six-week gap between defect setting and im-
plantation of BMSCs, thereby inducing an early OA stage. In
addition, thus far only MSCs isolated from bone marrow have
been used. Other MSC sources, for example adipose tissue,
might provide many advantages because of easier cell prepa-
ration, a higher percentage of MSCs compared with differen-
tiated cells, and better availability. No study has been per-
formed using only BMCs to study the cartilage-regeneration
capacity of crude cell suspensions including those used fre-
quently for human treatment (see below). Most importantly, in
all studies (except the one from the Richter group [21]) no
specific marker for hypertrophic differentiation of the BMSCs
was evaluated and therefore no conclusion can be drawn
regarding the phenotypic stability of the implanted cells. Fur-
thermore, to find out under which conditions regenerated
tissue best reflects normal tissue-like properties, the overall
comparability between the study procedures must be
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improved with respect to follow-up times, scoring systems,
biomechanical measurements, and biochemical properties.
Human Clinical Studies Using Autologous MSC and BMC
for Treatment of Chondral and Osteochondral Lesions:
Promising Tissue-Engineering Approaches
Cartilage defects that arise from an underlying disease process
(for example OA) are distinct from focal cartilage lesions that
result from acute injury or osteochondrosis dissecans, and this
difference must always be taken into consideration. Specifi-
cally, acute cartilage injury and osteochondrosis dissecans
often occur in otherwise healthy joints; the patient might be
young, and probably only the focal defect will require local-
ized treatment. In contrast, patients with OA are likely to be
elderly, and often the entire articulating surface will require
treatment. Repair of lesions may provide symptomatic relief
and delay the progression of OA symptoms, but without
effective treatment of the underlying disease any improvement
is likely to be short-lived [34]. Thus, common to all types of
cell-based therapy is that they are not recommended for treat-
ment of expanded, arthritic cartilage lesions and kissing le-
sions. Rather, they are recommended for treatment of local,
full-thickness chondral and osteochondral defects, ideally
with an intact cartilage interface [35].
Trauma-Induced Chondral and Osteochondral Defects
Microfracturing If an articular cartilage lesion below 1–4 cm2
is confirmed, the first choice of treatment is often
microfracturing (MFX), the penetration of the subchondral
bone plate by creating small holes. Bleeding from the
subchondral bone spaces yields a blood clot (often called
superclot), which is believed capable of stimulating attraction,
proliferation, and chondrogenic differentiation of MSCs aris-
ing from the bone marrow. The advantage of a marrow-
stimulating technique is that several of the main objectives
of cartilage repair are fulfilled: it is an easy, simple, minimally
invasive, low-morbidity, and single-stage procedure, and is a
cost-effective technology with few associated complications
and a high capacity for creation of durable cartilage-repair
tissue that can delay the time to joint replacement [36, 37].
However, clinical results are age-dependent. Marrow stimula-
tion results in improved function and reduced pain for up to
75 % of young patients after five years and up to 80 % of
patients after an average of 11 years of follow-up [38, 39].
Repair tissue is mostly fibrocartilage or a hybrid of hyaline
and fibrous cartilage, of inferior quality and mechanical sta-
bility compared with the original cartilage matrix. Formation
of an insufficient cartilage ECM might be promoted by an
inadequate microenvironment of the superclot, because its
composition is poorly defined. Other limitations are that only
partial defect filling is achieved, because of shrinking of the
superclot and low incidence of MSCs in the bone-marrow
fraction (Reviewed in [37, 40]).
Application of BMC to Trauma-Induced Defects MSC can be
used as a cell suspension expanded by culture or from bone-
marrow concentrate (BMC). However, these products differ
profoundly in composition. The advantage of using BMC
over cultured MSCs is that the cells are not passaged, but
the disadvantage is that BMC gives a more heterogeneous
composition compared with expanded MSC [41•]. Studies
have been reported in which BMC, usually combined with
other regenerative techniques, is applied to trauma-induced
human-cartilage defects. The group of Gigante published
three case series in which they treated five patients with
isolated femoral condyle lesions by combining BMC with
the autologous matrix-induced chondrogenesis (AMIC) tech-
nique [42]. In a second study, they described a novel arthros-
copy technique that combines MFX, autologous BMC, and a
protective collagen-based scaffold [43]. The objective of both
procedures is to augment the original single-stage procedure
with BMC and to increase defect filling and the rate of
hyaline-like-cartilage regeneration. The procedure combining
MFX, BMC, and a protective collagen scaffold is inexpensive
and reproducible and has obtained regeneration of hyaline-
like cartilage. A third study from this group reported on a
combination of MFX, BMC, and resorbable polyglycolic
acid–hyaluronic acid (PGA–HA) membranes. Nine patients
with focal lesions of the condylar articular cartilage were
consecutively treated with arthroscopic PGA–HA-covered
MFX and BMC. Macroscopic assessment of cartilage after
12 months revealed that one repair attempt appeared normal,
three almost normal, and one abnormal. Histological analysis
revealed hyaline-like-cartilage-repair-tissue formation in one
case and MRI at 8–12 months follow-up revealed complete
defect filling [44•]. A comparable approach to treating
osteochondral knee and talar dome lesions is reported by the
Giannini group, who combined BMC and HA-scaffolds (or
collagen powder) with platelet-rich fibrin (PRF) gel in a one-
step repair technique and treated 48 patients, with an average
follow-up of 24–35 months. Histological evaluation revealed
regenerated tissue with a variety of degrees of remodeling
irrespective of biomaterial used, although none had en-
tirely hyaline cartilage. These data suggest the one-step
technique is a possible alternative for cartilage repair,
obtaining improved functional scores and overcoming
the disadvantages of previous techniques [45]. In this line,
a recent case-series study reported treatment of large
cartilage lesions of up to 12 cm2 (ICRS grade III–IV)
with BMC, resulting in significant improvement in all
clinical scores for 52 out of 54 patients [46]. In a study
comparing BMC, open autologous chondrocyte implanta-
tion (ACI), and ACI arthroscopy, clinical improvement
was similar in all three groups [47] (Table 2).
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Application of Expanded BMSC to Trauma-Induced
Defects The second principal treatment strategy, using ex-
panded BMSC, might be difficult to manage from a legal
perspective (because it is regarded as pharmacological
drug administration), but positive results have been report-
ed from preclinical animal and clinical human studies. The
advantage of expanded MSC is a higher number of cells;
the disadvantage is an increased contamination risk during
expansion [41•]. The Wakitani group was the first to trans-
plant autologous BMSC, aspirated from the iliac crest and
embedded in a collagen gel; these were transplanted into
full-thickness patella-femoral-articular-cartilage defects of
two patients and covered with a periosteal flap. Although
clinical symptoms were improved, histological evaluation
12 months later revealed that the defects were filled with
fibrocartilage and not with hyaline-like-cartilage tissue
[48]. Three years later the group used the same procedure
to implant BMSC into full-thickness cartilage defects of
patella-femoral joints. Again, clinical symptoms improved
and were maintained throughout the follow-up period.
However, it was not possible to unambiguously determine
whether the defects were repaired with hyaline cartilage,
although biopsies were safranin-O or toluidine-blue posi-
tive. Much more likely was that the defects were filled with
fibrocartilage-like tissue [49, 50]. In 2010, Haleem et al.
transplanted BMSC embedded in platelet-rich fibrin glue
(PRF) into full-thickness cartilage defects; compared with
the collagen sheet (bovine and porcine origin) PRF has the
advantages of being autologous and bio-resorbable. On the
basis of MRI, after 12 months the authors concluded that in
three out of five patients the defects were filled with tissue
resembling native cartilage without signs of hypertrophy
[51]. The only comparative study, reported by Nejadnik
et al., compared transplantation outcomes for autologous
col lagen-embedded BMSC versus chondroctyes
transplanted into full-thickness knee-cartilage defects in a
cohort study. Analysis after an up-to-two-years follow-up
period revealed similar functional and clinical results, with
the clear advantage that the BMSC treatment required only
one operation and minimized donor-site morbidity [52].
These cartilage-repair techniques were able to generate
repair tissue which up to a certain point approximates the
characteristics of naive hyaline cartilage, but which still
more closely represents undesired fibrocartilage tissue.
MSC and BMC treatment strategies obtained a marked
reduction in procedure, morbidity, and cost by using a
“one step” technique able to overcome all the disadvan-
tages of previous repair techniques. However, clinical
data on both strategies (i.e. delivering cultured MSC or
BMC to the defect site), although promising, must be
regarded as preliminary because most reported studies
were single or series case studies without valid and sound
controls (Table 2).
OA-Induced Defects
The above intervention strategies were performed mostly on
younger patients without clinical and radiological symptoms
of OA. Important for the choice of cell-application strategies is
the fact that OA is a chronic disease which results in multiple
cartilage lesions during pathogenesis, whereas trauma in gen-
eral results in a single localized chondral or osteochondral
defect. Therefore, the easiest way to treat OA-mediated le-
sions would be intraarticular injection of MSC or BMC.
Injection of BMC In a study by Varma et al., 50 patients with
mild to moderate knee OAwere selected and divided into two
groups. One group received arthroscopic debridement alone
and the other received buffy coat (mesenchymal-stem-cell
concentrate) injection with the arthroscopic debridement. On
follow-up, patients were assessed on the basis of visual ana-
logue scale (VAS) score and OA outcome score. The results
suggest that injection of BMCmuch improved the overall OA
outcome score, especially the quality of life within and at the
end of the follow-up period [53]. A more recent study by Kim
et al. used combined intraarticular injection of autologous
BMC and adipose tissue (BMAC) into the knees of 41
patients with radiographically assessed OA (assessed on
the basis of the Kellgren–Lawrence (K–L) grade I–IV
scale). BMAC injection significantly improved both knee
pain and function in all patients. The authors suggest that
the injection would be even more effective in early to
moderate phases of OA [54•] (Table 2).
Injection of BMSCs and ADMSCs There are several case
reports in which BMSCs expanded in vitro were injected
into OA joints. The approach of Centeno et al. [55] is
interesting, because they augmented the single BMSC
injection with autologous platelet lysates prepared from
platelet-rich-plasma (PRP) aspirates. The pre and post-
procedure MRI analysis revealed increased meniscus and
cartilage volume, and at three-month follow-up the mod-
ified VAS scores decreased by 95 %. Two subsequent
uncontrolled studies from the same group using the same
treatment procedure were conducted on a large group of
patients suffering from OA and other intraarticular pathol-
ogy [56, 57]. However, only approximately 60 % of the
patients had knee improvement scores thereafter. In this
line, suboptimal results were reported after a single injec-
tion of expanded and partially characterized BMSCs. This
study was a phase-one clinical trial which recruited six
patients with radiological evidence of knee OA requiring
joint-replacement surgery. Pain, functional status of the
knee, and walking distance tended to improve up to six
months post-injection, after which pain seemed to be
slightly increased and the walking ability of the patients
slightly decreased. Comparison of MRI at baseline and six
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months after the stem-cell injection revealed increased
cartilage thickness, increased extension of the repair tissue
over the subchondral bone, and much-reduced size of
subchondral bone-marrow lesions in three out of six pa-
tients [58•]. Similar results were obtained in a second
uncontrolled pilot study [59].
Of much clinical interest would be the use of ADSCs
obtained from lipoaspirates, which offer several advantages
over BMSCs when used for cartilage-tissue engineering.
ADSCs are more abundant and easily available, and they
confer a similar potential to differentiate and to direct forma-
tion of cartilage-like tissue. In 2011, Pak et al. [60•] reported
good results after treatment of two patients affected by knee
OAwith the injection of concentrated ADSCs (not expanded
or cultured) together with hyaluronic acid (HA), dexametha-
sone, and PRP. Concentrated ADSCswere obtained by double
centrifugation of lipoaspirates and digestion with collagenase.
After three months subjective pain and functional status im-
proved, and MRI revealed significantly increased cartilage
thickness [60•]. This was followed by three studies from
Koh et al. [61], who used concentrated ADSCs derived from
the infrapatellar fatpad for treatment of knee OA. First, they
presented a case-control study with a total of 25 patients, who
each received a single injection of ADSCs and, subsequently,
PRP [61]. Clinical results were promising, and the group
conducted two further case studies (not controlled) with a
similar treatment procedure, but with a different source of
ADSCs in the second study. All applied clinical outcome
and MRI cartilage scores improved significantly [62, 63].
These studies suggest that ADSC therapy for knee OA is
effective in promoting cartilage healing, reducing pain, and
improving function, and therefore seems to be a promising
option for OA treatment in elderly patients (Table 2).
Implantation of BMSCs and ADSCs The first report describ-
ing the implantation of expanded BMSCs into OA knee
lesions also came from the Wakitani group. They conducted
a comparative study on patients who had undergone high
tibial osteotomy (HTO) because of OA. Twelve patients re-
ceived transplantation with expanded autologous BMSCs,
which were embedded in a gel composed of type I collagen
and implanted as a collagen sheet, and 12 patients served as
cell-free controls receiving the collagen sheet alone. The
BMSC–collagen construct was positioned into a large defect
of the medial femoral condyle, where cartilage was lost and
subchondral bone was exposed, and covered with a periosteal
flap. Approximately a year later clinical scores did not differ
between the groups, but arthroscopy and histological scores
were better in the cell-transplanted group [64]. In a recent
report from the Koh group, ADSCs were implanted into an
isolated full-thickness cartilage lesion in OA knees. Patients
with multiple cartilage lesions were excluded, as were those
with a history of marrow-stimulation procedures, i.e. MFX or
subchondral drilling. Directly after isolation from fat tissue,
cells were dripped into the cartilage lesion and the knee was
held in a stationary position for 10 min. No supporting bio-
material was used, nor were the cells kept in position by
covering with a matrix or periosteal flap, but simple adherence
to the subchondral bone was permitted. Although the authors
suggested that MSC implantation could have great potential
for treating OA lesions, the second-look arthroscopy findings
revealed that in 76 % of the patients the repair was abnormal
or severely abnormal by ICRS standards. They concluded that
the development of an advanced surgical procedure with
tissue-engineered scaffolds may be needed to treat patients
with OA-induced large cartilage lesions [65•].
In general, it is not recommended that the MFX technique
alone should be used for treatment of OA-mediated degener-
ative cartilage lesions. However, in a recent randomized,
controlled clinical study, MFX combined with intraarticular
injection of BMSCs was used to treat 28 patients with uni-
compartmental OA knees undergoing HTO, whereas the sec-
ond group of 28 patients received an intraarticular HA injec-
tion instead. Assessment of IKDC andMOCARTscores up to
two years post-surgery revealed significantly higher scores in
the cell-treated group [66].
Concerns Regarding Current Clinical-Treatment
Procedures There are several common limitations, of which
at least one applies to each clinical study listed. First and most
importantly, most studies lack quantitative and histological
evidence. Second, many studies are level IV studies, and
therefore either no matched control group is included or the
number of cases is very small. In addition, the follow-up
period is often too short and it would be desirable to have
more than one arthroscopy observation during the follow-up
time. The latter, of course, is associated with ethical concerns.
Third, almost every study used different treatment procedures,
i.e. intraarticular injection versus implantation or including
MSCs from different tissue sources, and thus they can be
regarded only as pilot studies.
Conclusions
Only a few published pre-clinical, large animal, and clinical
studies of MSC-based treatment of OA-induced chondral and
osteochondral lesions are available (Fig. 1). Most pre-clinical
studies using large-animal models provide MSC-based treat-
ment procedures for isolated focal chondral and osteochondral
lesions encompassed by healthy cartilage and bone. Further-
more, they do not address special requirements for cell-based
strategies adapted to treat OA-induced degenerative large
cartilage defects. In addition, all studies used expanded
BMSCs, requiring a two-step treatment, and none used
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BMC, which have important clinical implications because
they can be applied without leaving the operating theatre,
circumventing regulatory obstacles. Clinical studies are most-
ly uncontrolled case reports including only a few patients, and
detailed molecular and histological analyses of repair tissue
are not feasible for ethical reasons. In addition, study proce-
dures, follow-up times, cell sources, and biomaterials differ
greatly among the studies, thereby preventing generalized
conclusions on clinical and functional outcomes. However,
preliminary results of pre-clinical and clinical studies are
promising. In general, after cell-based therapy—irrespective
of cell type—clinical and functional scores are clearly im-
proved and defects are filled with newly formed cartilage-like
tissue, sometimes even with hyaline-like characteristics.
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